Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brixadi vs Vivitrol: Brain Mechanisms of Cognitive Response in OUD
NCT04454411Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: functional Magnetic Resonance Imaging Signal at 90 days and Opioid Urine Toxicology at 120 days. Started Aug 2022; status: terminated.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04454411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454411.